Natera Announces First Quarter 2022 Earnings Conference Call
Natera, a leader in cell-free DNA testing, will release its Q1 2022 financial results on May 5, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Natera, a leader in cell-free DNA testing, will release its Q1 2022 financial results on May 5, 2022, after market close. A conference call will follow at 1:30 PM PT to discuss these results and future outlook. The company's operations span oncology, women's health, and organ health, supported by over 100 peer-reviewed studies affirming their test accuracy. Natera is committed to integrating personalized genetic testing into standard care, thereby enhancing patient health.
Positive
- Company is a leader in cell-free DNA testing with a strong focus on oncology and women's health.
- Natera's tests are supported by over 100 peer-reviewed publications ensuring high accuracy.
Negative
- None.
Details
News Market Reaction – NTRA
The recorded move for NTRA in the trading session of this news was +6.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, May 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2022, after the market close on May 5, 2022. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Earnings Conference Call Information:
Event: | Natera's First Quarter 2022 Financial Results Conference Call |
Date: | Thursday, May 5, 2022 |
Time: | 1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In: | (877) 823-0171, Domestic |
(617) 500-6932, International | |
Password: | 9390955 |
Webcast: |
A webcast replay will be available at investor.natera.com.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., pr@natera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/natera-announces-first-quarter-2022-earnings-conference-call-301536935.html
SOURCE Natera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.